Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A qualitative study indicates that there is a positive selection bias towards favourable economic analysis of targeted therapies, when these are funded by the manufacturer. At a time of increasing budgetary constraints and public scrutiny of the relationship between industry and the professions, we need a more mixed economy of funding for this field. © 2012 Macmillan Publishers Limited. All rights reserved.

Original publication

DOI

10.1038/nrclinonc.2012.75

Type

Journal article

Journal

Nature Reviews Clinical Oncology

Publication Date

01/06/2012

Volume

9

Pages

309 - 310